Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2021 Earnings Results

Alnylam Pharmaceuticals Beats on EPS, Stock Up 0.48%

Alnylam Pharmaceuticals reported a narrower-than-expected loss per share, which contributed to a slight increase in stock price. The positive EPS surprise indicates better-than-anticipated cost management or operational efficiency. However, the lack of revenue data and guidance leaves some uncertainty about future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.30	N/A	+17.09%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the quarter's performance, particularly in terms of EPS. They emphasized their commitment to ongoing pipeline development.

We are pleased with our progress this quarter.

Our focus remains on advancing our pipeline.

Alnylam Pharmaceuticals Beats on EPS, Stock Up 0.48%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Beats on EPS, Stock Up 0.48%

Key numbers

Management commentary